|

Befotertinib Clinical Trials

4 actively recruiting trials

Also known as: D-0316

Pipeline

Phase 2: 3Phase 4: 1

Top Sponsors

  • Sun Yat-sen University1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Fudan University1
  • Betta Pharmaceuticals Co., Ltd.1

Indications

  • Lung Cancer4
  • Cancer4
  • Adjuvant Drug Therapy1
  • EGFR S768I1
  • EGFR L861Q1

Other4 trials

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
Phase 4
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Phase 2
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
Phase 2
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.